Benjamin Shum
A5004484216- Cancer Genomics and Diagnostics
- Melanoma and MAPK Pathways
- Cutaneous Melanoma Detection and Management
- Cancer Immunotherapy and Biomarkers
- COVID-19 Clinical Research Studies
- SARS-CoV-2 and COVID-19 Research
- Computational Drug Discovery Methods
- COVID-19 and healthcare impacts
- Immunotherapy and Immune Responses
- Cell Image Analysis Techniques
- CAR-T cell therapy research
- vaccines and immunoinformatics approaches
- Immune Cell Function and Interaction
- Renal cell carcinoma treatment
- Ocular Oncology and Treatments
- Prostate Cancer Treatment and Research
- Molecular Biology Techniques and Applications
- Pancreatic and Hepatic Oncology Research
- Medical Imaging and Pathology Studies
- Lymphoma Diagnosis and Treatment
- Cancer, Hypoxia, and Metabolism
- Immune responses and vaccinations
- Diabetes and associated disorders
- Long-Term Effects of COVID-19
- Ubiquitin and proteasome pathways
The Francis Crick Institute
2020-2023
Royal Marsden Hospital
2021-2023
Royal Marsden NHS Foundation Trust
2020-2023
Institute of Cancer Research
2023
National Health Service
2021
University College London
2021
London Cancer
2021
Royal Prince Alfred Hospital
2017
Abstract Coronavirus disease 2019 (COVID-19) antiviral response in a pan-tumor immune monitoring (CAPTURE) ( NCT03226886 ) is prospective cohort study of COVID-19 immunity patients with cancer. Here we evaluated 585 following administration two doses BNT162b2 or AZD1222 vaccines, administered 12 weeks apart. Seroconversion rates after were 85% and 59% solid hematological malignancies, respectively. A lower proportion had detectable titers neutralizing antibodies (NAbT) against severe acute...
Abstract Patients with cancer are currently prioritized in coronavirus disease 2019 (COVID-19) vaccination programs globally, which includes administration of mRNA vaccines. Cytokine release syndrome (CRS) has not been reported vaccines and is an extremely rare immune-related adverse event immune checkpoint inhibitors. We present a case CRS that occurred 5 d after BTN162b2 (tozinameran)—the Pfizer-BioNTech COVID-19 vaccine—in patient colorectal on long-standing anti-PD-1 monotherapy. The was...
Patients with cancer have higher COVID-19 morbidity and mortality. Here we present the prospective CAPTURE study, integrating longitudinal immune profiling clinical annotation. Of 357 patients cancer, 118 were SARS-CoV-2 positive, 94 symptomatic 2 died of COVID-19. In this cohort, 83% had S1-reactive antibodies 82% neutralizing against wild type SARS-CoV-2, whereas antibody titers Alpha, Beta Delta variants substantially reduced. levels decreased in 13% patients, remained stable for up to...
Abstract Understanding the evolutionary pathways to metastasis and resistance immune-checkpoint inhibitors (ICI) in melanoma is critical for improving outcomes. Here, we present most comprehensive intrapatient metastatic dataset assembled date as part of Posthumous Evaluation Advanced Cancer Environment (PEACE) research autopsy program, including 222 exome sequencing, 493 panel-sequenced, 161 RNA 22 single-cell whole-genome sequencing samples from 14 ICI-treated patients. We observed...
Although thousands of solid tumors have been sequenced to date, a fundamental under-sampling bias is inherent in current methodologies. This caused by tissue sample input fixed dimensions (e.g., 6 mm biopsy), which becomes grossly under-powered as tumor volume scales. Here, we demonstrate representative sequencing (Rep-Seq) new method achieve unbiased sampling. Rep-Seq uses residual material, homogenized and subjected next-generation sequencing. Analysis intratumor mutation burden (TMB)...
Checkpoint inhibitor-related hepatitis (CPI-Hep) is an emerging clinical challenge. We aimed to gain insights into the immunopathology of CPI-Hep by comprehensively characterising myeloid and lymphoid subsets.
Patients with blood cancer continue to have a greater risk of inadequate immune responses following three COVID-19 vaccine doses and severe disease. In the context CAPTURE study (NCT03226886), we report in 80 patients who received fourth dose BNT162b2. We measured neutralizing antibody titers (NAbTs) using live virus microneutralization assay against wild-type (WT), Delta, Omicron BA.1 BA.2 T cell WT an activation-induced marker (AIM) assay. The proportion detectable NAb after increased...
Introduction Systemic corticosteroids are the mainstay of treatment for immune checkpoint inhibitor induced (CPI) colitis but associated with complications including life-threatening infection. The topically acting oral corticosteroid beclomethasone dipropionate (BD) is an effective mild to moderate flares ulcerative colitis, and has fewer side effects than systemic corticosteroids. We hypothesized that BD would be CPI-induced colitis. Methods performed a retrospective analysis all patients...
SUMMARY There is a pressing need to characterise the nature, extent and duration of immune response SARS-CoV-2 in cancer patients inform risk-reduction strategies preserve outcomes. CAPTURE prospective, longitudinal cohort study healthcare workers (HCWs) integrating profiling clinical annotation. We evaluated 529 blood samples 1051 oronasopharyngeal swabs from 144 73 HCWs correlated with >200 variables. In solid cancers HCWs, S1-reactive neutralising antibodies were detectable five months...
Patients with cancer have higher COVID-19 morbidity and mortality. Here we present the prospective CAPTURE study (NCT03226886) integrating longitudinal immune profiling clinical annotation. Of 357 patients cancer, 118 were SARS-CoV-2-positive, 94 symptomatic 2 died of COVID-19. In this cohort, 83% had S1-reactive antibodies, 82% neutralizing antibodies against WT, whereas antibody titers (NAbT) Alpha, Beta, Delta variants substantially reduced. Whereas levels decreased in 13% patients, NAbT...
<div>Abstract<p>Understanding the evolutionary pathways to metastasis and resistance immune checkpoint inhibitors (ICI) in melanoma is critical for improving outcomes. Here we present most comprehensive intra-patient metastatic dataset assembled date as part of PEACE research autopsy programme, including 222 exome, 493 panel-sequenced, 161 RNA-seq, 22 single-cell whole-genome sequencing samples from 14 ICI-treated patients. We observed frequent doubling widespread loss...
<p>Supplementary figure 1: Cohort overview. Number of samples sequenced with whole exome, panel or RNA sequencing. Supplementary 2: Phylogeny and WGD events in CRUKP1047. 3: Ploidy SCNA burden. 4: Overview each case. 5: MEDICC2 copy number sample trees. 6: MEDICC tree all exome demonstrating that cluster together by patient, not melanoma subtype. 7: frequency cutaneous (a), acral (b) unknown primary (MUP, c). 8: Correlation between liver distance to other sites time emergence after...
<p>Supplementary figure 1: Cohort overview. Number of samples sequenced with whole exome, panel or RNA sequencing. Supplementary 2: Phylogeny and WGD events in CRUKP1047. 3: Ploidy SCNA burden. 4: Overview each case. 5: MEDICC2 copy number sample trees. 6: MEDICC tree all exome demonstrating that cluster together by patient, not melanoma subtype. 7: frequency cutaneous (a), acral (b) unknown primary (MUP, c). 8: Correlation between liver distance to other sites time emergence after...